Bagdat Ashimbekova
Bagdat Ashimbekova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Akbota Skenderova
Department of Internal Medicine, Faculty of Medicine, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 160000, Kazakhstan
1 shared publication - Arailym Tastemirova
Department of Biology, Nazarbayev Intellectual School of Science and Mathematics, Turkestan 160000, Kazakhstan
1 shared publication - Bakhyt Baizakova
Department of Internal Medicine, Faculty of Medicine, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 160000, Kazakhstan
1 shared publication - Elmira Kozhambekova
Department of Surgery and Pediatric Dentistry, Faculty of Dentistry, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 160000, Kazakhstan
1 shared publication - Ibragim Ishigov
Department of Fundamental Medical Sciences, Faculty of Dentistry, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 160000, Kazakhstan
1 shared publication - Kozakhmet Baimyrza
Department of Surgery and Pediatric Dentistry, Faculty of Dentistry, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 160000, Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (1) , 20
Camel Milk-Based Fermented Product “Inullact-Fito” Ameliorates Metabolic and Immunological Disturbances in Alloxan-Induced Diabetes
Background/Objectives: This study examined the metabolic, oxidative, immunological, and histomorphological effects of the multicomponent fermented biological product derived from camel milk, Inullact-Fito, in comparison to metformin in a rat model of alloxan-induced diabetes resulting from insulin insufficiency. The model was chosen as an experimental system that replicates pancreatic β-cell damage induced by oxidative stress rather than insulin resistance. Methods: Alloxan-induced diabetes was used to evaluate metabolic, oxidative, immunological, and histomorphological alterations. Metformin was utilized as a pharmacological comparator. Blood glucose levels, circulating insulin concentrations, markers of oxidative stress and lipid peroxidation, immunoglobulin levels, CD4+/CD8+ T cell balance, and pancreatic histostructure were assessed. Results: Alloxan administration led to substantial hyperglycemia, oxidative stress, immunological imbalance, and structural damage to pancreatic tissue. Following therapy with Inullact-Fito, blood glucose levels reduced dramatically (from 21.9 ± 0.22 to 9.85 ± 0.10 mmol/L, p < 0.05), circulating insulin concentrations were largely corrected, oxidative stress and lipid peroxidation markers decreased. Immunological evaluation revealed decreased serum immunoglobulin M and IgG levels (p < 0.05) and partial normalization of the CD4+/CD8+ T cell balance. Metformin showed comparative effects; however, its activity in this model is limited by its primary mechanism related to insulin resistance. Conclusions: Overall, the data reveal that Inullact-Fito combines metabolic, antioxidant, and immunomodulatory actions under experimental oxidative and metabolic stress conditions. Further research using models of insulin resistance and type 2 diabetes, as well as long-term clinical trials, is needed to fully evaluate the therapeutic potential, safety profile, and translational importance of this fermented dairy product as a functional nutritional intervention.
- 12 January 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (1) , 20
Open AccessCamel Milk-Based Fermented Product “Inullact-Fito” Ameliorates Metabolic and Immunological Disturbances in Alloxan-Induced Diabetes
Background/Objectives: This study examined the metabolic, oxidative, immunological, and histomorphological effects of the multicomponent fermented biological product derived from camel milk, Inullact-Fito, in comparison to metformin in a rat model of alloxan-induced diabetes resulting from insulin insufficiency. The model was chosen as an experimental system that replicates pancreatic β-cell damage induced by oxidative stress rather than insulin resistance. Methods: Alloxan-induced diabetes was used to evaluate metabolic, oxidative, immunological, and histomorphological alterations. Metformin was utilized as a pharmacological comparator. Blood glucose levels, circulating insulin concentrations, markers of oxidative stress and lipid peroxidation, immunoglobulin levels, CD4+/CD8+ T cell balance, and pancreatic histostructure were assessed. Results: Alloxan administration led to substantial hyperglycemia, oxidative stress, immunological imbalance, and structural damage to pancreatic tissue. Following therapy with Inullact-Fito, blood glucose levels reduced dramatically (from 21.9 ± 0.22 to 9.85 ± 0.10 mmol/L, p < 0.05), circulating insulin concentrations were largely corrected, oxidative stress and lipid peroxidation markers decreased. Immunological evaluation revealed decreased serum immunoglobulin M and IgG levels (p < 0.05) and partial normalization of the CD4+/CD8+ T cell balance. Metformin showed comparative effects; however, its activity in this model is limited by its primary mechanism related to insulin resistance. Conclusions: Overall, the data reveal that Inullact-Fito combines metabolic, antioxidant, and immunomodulatory actions under experimental oxidative and metabolic stress conditions. Further research using models of insulin resistance and type 2 diabetes, as well as long-term clinical trials, is needed to fully evaluate the therapeutic potential, safety profile, and translational importance of this fermented dairy product as a functional nutritional intervention.